Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Repare Therapeutics Inc. (RPTX : NSDQ)

• Company Description    Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada. Number of Employees: 180

• Price / Volume Information    Yesterday's Closing Price: $10.63 Daily Weekly Monthly 20 Day Moving Average: 92,650 shares Shares Outstanding: 42.09 (millions) Market Capitalization: $447.40 (millions) Beta: 0.06 52 Week High: $18.68 52 Week Low: $8.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.27% 3.20% 12 Week 3.51% -3.92% Year To Date -27.74% -34.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7210 Frederick-Banting Suite 100 - St-Laurent,A8 H4S 2A1 CAN ph: 857-412-7018 fax: - investor@reparerx.com http://www.reparerx.com

• General Corporate Information    Officers Lloyd M. Segal - President; Chief Executive Officer and Director Thomas Civik - Chairman Steve Forte - Executive Vice President and Chief Financial Offic David Bonita - Director Jerel Davis - Director Peer Information Repare Therapeutics Inc. (CORR.) Repare Therapeutics Inc. (RSPI) Repare Therapeutics Inc. (CGXP) Repare Therapeutics Inc. (BGEN) Repare Therapeutics Inc. (GTBP) Repare Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 760273102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/03/23 Share - Related Items Shares Outstanding: 42.09 Most Recent Split Date: (:1) Beta: 0.06 Market Capitalization: $447.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.78 Price/Cash Flow: - Price / Sales: 3.26 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -10.67% Sales Growth vs. Year Ago Period: 1,291.67% vs. Previous Quarter: -68.80% ROE 03/31/23 - -11.01 12/31/22 - -10.86 09/30/22 - -9.53 ROA 03/31/23 - -8.25 12/31/22 - -8.19 09/30/22 - -7.22 Current Ratio 03/31/23 - 4.02 12/31/22 - 4.50 09/30/22 - 6.31 Quick Ratio 03/31/23 - 4.02 12/31/22 - 4.50 09/30/22 - 6.31 Operating Margin 03/31/23 - -21.32 12/31/22 - -22.03 09/30/22 - -21.31 Net Margin 03/31/23 - -21.32 12/31/22 - -22.03 09/30/22 - -21.31 Pre-Tax Margin 03/31/23 - -7.66 12/31/22 - -10.54 09/30/22 - -21.55 Book Value 03/31/23 - 5.97 12/31/22 - 6.66 09/30/22 - 7.29 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©